Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
Identifieur interne : 002913 ( PubMed/Corpus ); précédent : 002912; suivant : 002914Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
Auteurs : Fred Saad ; Neal Shore ; Hendrik Van Poppel ; Dana E. Rathkopf ; Matthew R. Smith ; Johann S. De Bono ; Christopher J. Logothetis ; Paul De Souza ; Karim Fizazi ; Peter F A. Mulders ; Paul Mainwaring ; John D. Hainsworth ; Tomasz M. Beer ; Scott North ; Yves Fradet ; Thomas A. Griffin ; Peter De Porre ; Anil Londhe ; Thian Kheoh ; Eric J. Small ; Howard I. Scher ; Arturo Molina ; Charles J. RyanSource :
- European urology [ 1873-7560 ] ; 2015.
English descriptors
- KwdEn :
- Abiraterone Acetate (adverse effects), Abiraterone Acetate (therapeutic use), Aged, Antineoplastic Agents, Hormonal (adverse effects), Antineoplastic Agents, Hormonal (therapeutic use), Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Bisphosphonate-Associated Osteonecrosis of the Jaw (etiology), Bone Density Conservation Agents (adverse effects), Bone Density Conservation Agents (therapeutic use), Bone Neoplasms (drug therapy), Bone Neoplasms (mortality), Bone Neoplasms (secondary), Clinical Trials, Phase III as Topic, Disease-Free Survival, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multicenter Studies as Topic, Odds Ratio, Prednisone (therapeutic use), Proportional Hazards Models, Prostatic Neoplasms, Castration-Resistant (drug therapy), Prostatic Neoplasms, Castration-Resistant (mortality), Prostatic Neoplasms, Castration-Resistant (pathology), Randomized Controlled Trials as Topic, Retrospective Studies, Risk Factors, Steroid Synthesis Inhibitors (adverse effects), Steroid Synthesis Inhibitors (therapeutic use), Time Factors, Treatment Outcome.
- MESH :
- chemical , adverse effects : Abiraterone Acetate, Antineoplastic Agents, Hormonal, Bone Density Conservation Agents, Steroid Synthesis Inhibitors.
- chemical , therapeutic use : Abiraterone Acetate, Antineoplastic Agents, Hormonal, Bone Density Conservation Agents, Prednisone, Steroid Synthesis Inhibitors.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- drug therapy : Bone Neoplasms, Prostatic Neoplasms, Castration-Resistant.
- etiology : Bisphosphonate-Associated Osteonecrosis of the Jaw.
- mortality : Bone Neoplasms, Prostatic Neoplasms, Castration-Resistant.
- pathology : Prostatic Neoplasms, Castration-Resistant.
- secondary : Bone Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Aged, Clinical Trials, Phase III as Topic, Disease-Free Survival, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multicenter Studies as Topic, Odds Ratio, Proportional Hazards Models, Randomized Controlled Trials as Topic, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome.
Abstract
Metastatic castration-resistant prostate cancer (mCRPC) often involves bone, and bone-targeted therapy (BTT) has become part of the overall treatment strategy.
DOI: 10.1016/j.eururo.2015.04.032
PubMed: 25985882
Links to Exploration step
pubmed:25985882Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.</title><author><name sortKey="Saad, Fred" sort="Saad, Fred" uniqKey="Saad F" first="Fred" last="Saad">Fred Saad</name><affiliation><nlm:affiliation>University of Montréal, Montréal, Québec, Canada. Electronic address: fredsaad@videotron.ca.</nlm:affiliation></affiliation></author><author><name sortKey="Shore, Neal" sort="Shore, Neal" uniqKey="Shore N" first="Neal" last="Shore">Neal Shore</name><affiliation><nlm:affiliation>Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Van Poppel, Hendrik" sort="Van Poppel, Hendrik" uniqKey="Van Poppel H" first="Hendrik" last="Van Poppel">Hendrik Van Poppel</name><affiliation><nlm:affiliation>University Hospital Leuven, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Rathkopf, Dana E" sort="Rathkopf, Dana E" uniqKey="Rathkopf D" first="Dana E" last="Rathkopf">Dana E. Rathkopf</name><affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Smith, Matthew R" sort="Smith, Matthew R" uniqKey="Smith M" first="Matthew R" last="Smith">Matthew R. Smith</name><affiliation><nlm:affiliation>Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="De Bono, Johann S" sort="De Bono, Johann S" uniqKey="De Bono J" first="Johann S" last="De Bono">Johann S. De Bono</name><affiliation><nlm:affiliation>Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Logothetis, Christopher J" sort="Logothetis, Christopher J" uniqKey="Logothetis C" first="Christopher J" last="Logothetis">Christopher J. Logothetis</name><affiliation><nlm:affiliation>MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation></affiliation></author><author><name sortKey="De Souza, Paul" sort="De Souza, Paul" uniqKey="De Souza P" first="Paul" last="De Souza">Paul De Souza</name><affiliation><nlm:affiliation>University of Western Sydney School of Medicine, Ingham Institute, Liverpool, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name><affiliation><nlm:affiliation>Institut Gustave Roussy, University of Paris Sud, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Mulders, Peter F A" sort="Mulders, Peter F A" uniqKey="Mulders P" first="Peter F A" last="Mulders">Peter F A. Mulders</name><affiliation><nlm:affiliation>Radboud University Medical Centre, Nijmegen, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Mainwaring, Paul" sort="Mainwaring, Paul" uniqKey="Mainwaring P" first="Paul" last="Mainwaring">Paul Mainwaring</name><affiliation><nlm:affiliation>Hematology and Oncology Clinics of Australia, Brisbane, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hainsworth, John D" sort="Hainsworth, John D" uniqKey="Hainsworth J" first="John D" last="Hainsworth">John D. Hainsworth</name><affiliation><nlm:affiliation>Sarah Cannon Research Institute, Nashville, TN, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Beer, Tomasz M" sort="Beer, Tomasz M" uniqKey="Beer T" first="Tomasz M" last="Beer">Tomasz M. Beer</name><affiliation><nlm:affiliation>Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA.</nlm:affiliation></affiliation></author><author><name sortKey="North, Scott" sort="North, Scott" uniqKey="North S" first="Scott" last="North">Scott North</name><affiliation><nlm:affiliation>Cross Cancer Institute, Edmonton, Alberta, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Fradet, Yves" sort="Fradet, Yves" uniqKey="Fradet Y" first="Yves" last="Fradet">Yves Fradet</name><affiliation><nlm:affiliation>Laval University, Québec City, Québec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Griffin, Thomas A" sort="Griffin, Thomas A" uniqKey="Griffin T" first="Thomas A" last="Griffin">Thomas A. Griffin</name><affiliation><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="De Porre, Peter" sort="De Porre, Peter" uniqKey="De Porre P" first="Peter" last="De Porre">Peter De Porre</name><affiliation><nlm:affiliation>Janssen Research & Development, Beerse, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Londhe, Anil" sort="Londhe, Anil" uniqKey="Londhe A" first="Anil" last="Londhe">Anil Londhe</name><affiliation><nlm:affiliation>Janssen Research & Development, Raritan, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kheoh, Thian" sort="Kheoh, Thian" uniqKey="Kheoh T" first="Thian" last="Kheoh">Thian Kheoh</name><affiliation><nlm:affiliation>Janssen Research & Development, San Diego, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Small, Eric J" sort="Small, Eric J" uniqKey="Small E" first="Eric J" last="Small">Eric J. Small</name><affiliation><nlm:affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Scher, Howard I" sort="Scher, Howard I" uniqKey="Scher H" first="Howard I" last="Scher">Howard I. Scher</name><affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Molina, Arturo" sort="Molina, Arturo" uniqKey="Molina A" first="Arturo" last="Molina">Arturo Molina</name><affiliation><nlm:affiliation>Janssen Research & Development, Menlo Park, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ryan, Charles J" sort="Ryan, Charles J" uniqKey="Ryan C" first="Charles J" last="Ryan">Charles J. Ryan</name><affiliation><nlm:affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25985882</idno><idno type="pmid">25985882</idno><idno type="doi">10.1016/j.eururo.2015.04.032</idno><idno type="wicri:Area/PubMed/Corpus">002913</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002913</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.</title><author><name sortKey="Saad, Fred" sort="Saad, Fred" uniqKey="Saad F" first="Fred" last="Saad">Fred Saad</name><affiliation><nlm:affiliation>University of Montréal, Montréal, Québec, Canada. Electronic address: fredsaad@videotron.ca.</nlm:affiliation></affiliation></author><author><name sortKey="Shore, Neal" sort="Shore, Neal" uniqKey="Shore N" first="Neal" last="Shore">Neal Shore</name><affiliation><nlm:affiliation>Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Van Poppel, Hendrik" sort="Van Poppel, Hendrik" uniqKey="Van Poppel H" first="Hendrik" last="Van Poppel">Hendrik Van Poppel</name><affiliation><nlm:affiliation>University Hospital Leuven, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Rathkopf, Dana E" sort="Rathkopf, Dana E" uniqKey="Rathkopf D" first="Dana E" last="Rathkopf">Dana E. Rathkopf</name><affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Smith, Matthew R" sort="Smith, Matthew R" uniqKey="Smith M" first="Matthew R" last="Smith">Matthew R. Smith</name><affiliation><nlm:affiliation>Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="De Bono, Johann S" sort="De Bono, Johann S" uniqKey="De Bono J" first="Johann S" last="De Bono">Johann S. De Bono</name><affiliation><nlm:affiliation>Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Logothetis, Christopher J" sort="Logothetis, Christopher J" uniqKey="Logothetis C" first="Christopher J" last="Logothetis">Christopher J. Logothetis</name><affiliation><nlm:affiliation>MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation></affiliation></author><author><name sortKey="De Souza, Paul" sort="De Souza, Paul" uniqKey="De Souza P" first="Paul" last="De Souza">Paul De Souza</name><affiliation><nlm:affiliation>University of Western Sydney School of Medicine, Ingham Institute, Liverpool, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name><affiliation><nlm:affiliation>Institut Gustave Roussy, University of Paris Sud, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Mulders, Peter F A" sort="Mulders, Peter F A" uniqKey="Mulders P" first="Peter F A" last="Mulders">Peter F A. Mulders</name><affiliation><nlm:affiliation>Radboud University Medical Centre, Nijmegen, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Mainwaring, Paul" sort="Mainwaring, Paul" uniqKey="Mainwaring P" first="Paul" last="Mainwaring">Paul Mainwaring</name><affiliation><nlm:affiliation>Hematology and Oncology Clinics of Australia, Brisbane, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hainsworth, John D" sort="Hainsworth, John D" uniqKey="Hainsworth J" first="John D" last="Hainsworth">John D. Hainsworth</name><affiliation><nlm:affiliation>Sarah Cannon Research Institute, Nashville, TN, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Beer, Tomasz M" sort="Beer, Tomasz M" uniqKey="Beer T" first="Tomasz M" last="Beer">Tomasz M. Beer</name><affiliation><nlm:affiliation>Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA.</nlm:affiliation></affiliation></author><author><name sortKey="North, Scott" sort="North, Scott" uniqKey="North S" first="Scott" last="North">Scott North</name><affiliation><nlm:affiliation>Cross Cancer Institute, Edmonton, Alberta, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Fradet, Yves" sort="Fradet, Yves" uniqKey="Fradet Y" first="Yves" last="Fradet">Yves Fradet</name><affiliation><nlm:affiliation>Laval University, Québec City, Québec, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Griffin, Thomas A" sort="Griffin, Thomas A" uniqKey="Griffin T" first="Thomas A" last="Griffin">Thomas A. Griffin</name><affiliation><nlm:affiliation>Janssen Research & Development, Los Angeles, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="De Porre, Peter" sort="De Porre, Peter" uniqKey="De Porre P" first="Peter" last="De Porre">Peter De Porre</name><affiliation><nlm:affiliation>Janssen Research & Development, Beerse, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Londhe, Anil" sort="Londhe, Anil" uniqKey="Londhe A" first="Anil" last="Londhe">Anil Londhe</name><affiliation><nlm:affiliation>Janssen Research & Development, Raritan, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kheoh, Thian" sort="Kheoh, Thian" uniqKey="Kheoh T" first="Thian" last="Kheoh">Thian Kheoh</name><affiliation><nlm:affiliation>Janssen Research & Development, San Diego, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Small, Eric J" sort="Small, Eric J" uniqKey="Small E" first="Eric J" last="Small">Eric J. Small</name><affiliation><nlm:affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Scher, Howard I" sort="Scher, Howard I" uniqKey="Scher H" first="Howard I" last="Scher">Howard I. Scher</name><affiliation><nlm:affiliation>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Molina, Arturo" sort="Molina, Arturo" uniqKey="Molina A" first="Arturo" last="Molina">Arturo Molina</name><affiliation><nlm:affiliation>Janssen Research & Development, Menlo Park, CA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ryan, Charles J" sort="Ryan, Charles J" uniqKey="Ryan C" first="Charles J" last="Ryan">Charles J. Ryan</name><affiliation><nlm:affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">European urology</title><idno type="eISSN">1873-7560</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abiraterone Acetate (adverse effects)</term><term>Abiraterone Acetate (therapeutic use)</term><term>Aged</term><term>Antineoplastic Agents, Hormonal (adverse effects)</term><term>Antineoplastic Agents, Hormonal (therapeutic use)</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Bisphosphonate-Associated Osteonecrosis of the Jaw (etiology)</term><term>Bone Density Conservation Agents (adverse effects)</term><term>Bone Density Conservation Agents (therapeutic use)</term><term>Bone Neoplasms (drug therapy)</term><term>Bone Neoplasms (mortality)</term><term>Bone Neoplasms (secondary)</term><term>Clinical Trials, Phase III as Topic</term><term>Disease-Free Survival</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Male</term><term>Middle Aged</term><term>Multicenter Studies as Topic</term><term>Odds Ratio</term><term>Prednisone (therapeutic use)</term><term>Proportional Hazards Models</term><term>Prostatic Neoplasms, Castration-Resistant (drug therapy)</term><term>Prostatic Neoplasms, Castration-Resistant (mortality)</term><term>Prostatic Neoplasms, Castration-Resistant (pathology)</term><term>Randomized Controlled Trials as Topic</term><term>Retrospective Studies</term><term>Risk Factors</term><term>Steroid Synthesis Inhibitors (adverse effects)</term><term>Steroid Synthesis Inhibitors (therapeutic use)</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Abiraterone Acetate</term><term>Antineoplastic Agents, Hormonal</term><term>Bone Density Conservation Agents</term><term>Steroid Synthesis Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Abiraterone Acetate</term><term>Antineoplastic Agents, Hormonal</term><term>Bone Density Conservation Agents</term><term>Prednisone</term><term>Steroid Synthesis Inhibitors</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Bone Neoplasms</term><term>Prostatic Neoplasms, Castration-Resistant</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Bisphosphonate-Associated Osteonecrosis of the Jaw</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Bone Neoplasms</term><term>Prostatic Neoplasms, Castration-Resistant</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Prostatic Neoplasms, Castration-Resistant</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Bone Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Clinical Trials, Phase III as Topic</term><term>Disease-Free Survival</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Male</term><term>Middle Aged</term><term>Multicenter Studies as Topic</term><term>Odds Ratio</term><term>Proportional Hazards Models</term><term>Randomized Controlled Trials as Topic</term><term>Retrospective Studies</term><term>Risk Factors</term><term>Time Factors</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Metastatic castration-resistant prostate cancer (mCRPC) often involves bone, and bone-targeted therapy (BTT) has become part of the overall treatment strategy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25985882</PMID><DateCreated><Year>2015</Year><Month>09</Month><Day>04</Day></DateCreated><DateCompleted><Year>2016</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7560</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Oct</Month></PubDate></JournalIssue><Title>European urology</Title><ISOAbbreviation>Eur. Urol.</ISOAbbreviation></Journal><ArticleTitle>Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.</ArticleTitle><Pagination><MedlinePgn>570-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eururo.2015.04.032</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0302-2838(15)00374-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Metastatic castration-resistant prostate cancer (mCRPC) often involves bone, and bone-targeted therapy (BTT) has become part of the overall treatment strategy.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Investigation of outcomes for concomitant BTT in a post hoc analysis of the COU-AA-302 trial, which demonstrated an overall clinical benefit of abiraterone acetate (AA) plus prednisone over placebo plus prednisone in asymptomatic or mildly symptomatic chemotherapy-naïve mCRPC patients.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">This report describes the third interim analysis (prespecified at 55% overall survival [OS] events) for the COU-AA-302 trial.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Patients were grouped by concomitant BTT use or no BTT use.</AbstractText><AbstractText Label="OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS" NlmCategory="METHODS">Radiographic progression-free survival and OS were coprimary end points. This report describes the third interim analysis (prespecified at 55% OS events) and involves patients treated with or without concomitant BTT during the COU-AA-302 study. Median follow-up for OS was 27.1 mo. Median time-to-event variables with 95% confidence intervals (CIs) were estimated using the Kaplan-Meier method. Adjusted hazard ratios (HRs), 95% CIs, and p values for concomitant BTT versus no BTT were obtained via Cox models.</AbstractText><AbstractText Label="RESULTS AND LIMITATIONS" NlmCategory="CONCLUSIONS">While the post hoc nature of the analysis is a limitation, superiority of AA and prednisone versus prednisone alone was demonstrated for clinical outcomes with or without BTT use. Compared with no BTT use, concomitant BTT significantly improved OS (HR 0.75; p=0.01) and increased the time to ECOG deterioration (HR 0.75; p<0.001) and time to opiate use for cancer-related pain (HR 0.80; p=0.036). The safety profile of concomitant BTT with AA was similar to that reported for AA in the overall intent-to-treat population. Osteonecrosis of the jaw (all grade 1/2) with concomitant BTT use was reported in <3% of patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">AA with concomitant BTT was safe and well tolerated in men with chemotherapy-naïve mCRPC. The benefits of AA on clinical outcomes were increased with concomitant BTT.</AbstractText><AbstractText Label="PATIENT SUMMARY" NlmCategory="RESULTS">Treatment of advanced prostate cancer often includes bone-targeted therapy. This post hoc analysis showed that in patients with advanced prostate cancer who were treated with abiraterone acetate and prednisone in combination with bone-targeted therapy, there was a continued trend in prolongation of life when compared with patients treated with prednisone alone.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT00887198.</AbstractText><CopyrightInformation>Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saad</LastName><ForeName>Fred</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>University of Montréal, Montréal, Québec, Canada. Electronic address: fredsaad@videotron.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shore</LastName><ForeName>Neal</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Poppel</LastName><ForeName>Hendrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>University Hospital Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rathkopf</LastName><ForeName>Dana E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Matthew R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Bono</LastName><ForeName>Johann S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Logothetis</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Souza</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University of Western Sydney School of Medicine, Ingham Institute, Liverpool, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fizazi</LastName><ForeName>Karim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institut Gustave Roussy, University of Paris Sud, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulders</LastName><ForeName>Peter F A</ForeName><Initials>PF</Initials><AffiliationInfo><Affiliation>Radboud University Medical Centre, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mainwaring</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hematology and Oncology Clinics of Australia, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hainsworth</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Sarah Cannon Research Institute, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beer</LastName><ForeName>Tomasz M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>North</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cross Cancer Institute, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fradet</LastName><ForeName>Yves</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laval University, Québec City, Québec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffin</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Janssen Research & Development, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Porre</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Janssen Research & Development, Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Londhe</LastName><ForeName>Anil</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Janssen Research & Development, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kheoh</LastName><ForeName>Thian</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Janssen Research & Development, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scher</LastName><ForeName>Howard I</ForeName><Initials>HI</Initials><AffiliationInfo><Affiliation>Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina</LastName><ForeName>Arturo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Janssen Research & Development, Menlo Park, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Charles J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00887198</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Eur Urol</MedlineTA><NlmUniqueID>7512719</NlmUniqueID><ISSNLinking>0302-2838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050071">Bone Density Conservation Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065088">Steroid Synthesis Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EM5OCB9YJ6</RegistryNumber><NameOfSubstance UI="D000069501">Abiraterone Acetate</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur Urol. 2015 Oct;68(4):578-80</RefSource><PMID Version="1">26116295</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2008 Jul 1;113(1):193-201</RefSource><PMID Version="1">18459173</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 Nov;14(12):1193-9</RefSource><PMID Version="1">24075621</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Support Care Cancer. 2008 Aug;16(8):879-89</RefSource><PMID Version="1">18392862</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Genitourin Cancer. 2007 Sep;5(6):390-6</RefSource><PMID Version="1">17956712</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2004 Mar 1;100(5):892-9</RefSource><PMID Version="1">14983482</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Genitourin Cancer. 2013 Mar;11(1):20-6</RefSource><PMID Version="1">23021204</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Mar 1;26(7):1148-59</RefSource><PMID Version="1">18309951</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Treat Rev. 2013 May;39(3):275-89</RefSource><PMID Version="1">23107383</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Urol. 2013 Sep;10(9):522-8</RefSource><PMID Version="1">23797341</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Support Palliat Care. 2012 Sep;6(3):299-303</RefSource><PMID Version="1">22871982</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2012 Jan 7;379(9810):39-46</RefSource><PMID Version="1">22093187</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2011 Jun 15;17(12):3876-83</RefSource><PMID Version="1">21680543</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2001 Sep 27;345(13):948-55</RefSource><PMID Version="1">11575286</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68</RefSource><PMID Version="1">12359855</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Qual Life Res. 2007 May;16(4):571-5</RefSource><PMID Version="1">17294287</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Urol. 2011 Mar;185(3):787-94</RefSource><PMID Version="1">21239012</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2012 Oct;13(10):983-92</RefSource><PMID Version="1">22995653</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2014 Nov;66(5):815-25</RefSource><PMID Version="1">24647231</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29</RefSource><PMID Version="1">22237781</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 May 26;364(21):1995-2005</RefSource><PMID Version="1">21612468</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hum Pathol. 2000 May;31(5):578-83</RefSource><PMID Version="1">10836297</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2013 Mar 1;132(5):1133-45</RefSource><PMID Version="1">22752881</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Prostate Cancer. 2013;2013:210686</RefSource><PMID Version="1">24069538</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 Jan 10;368(2):138-48</RefSource><PMID Version="1">23228172</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2012 Dec;13(12 ):1210-7</RefSource><PMID Version="1">23142059</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2011 Mar 5;377(9768):813-22</RefSource><PMID Version="1">21353695</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Urol. 2006 Jan;175(1):27-34</RefSource><PMID Version="1">16406864</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Lett. 2012 Oct 28;323(2):135-46</RefSource><PMID Version="1">22521546</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000069501" MajorTopicYN="N">Abiraterone Acetate</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018931" MajorTopicYN="N">Antineoplastic Agents, Hormonal</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059266" MajorTopicYN="N">Bisphosphonate-Associated Osteonecrosis of the Jaw</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050071" MajorTopicYN="N">Bone Density Conservation Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001859" MajorTopicYN="N">Bone Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064129" MajorTopicYN="N">Prostatic Neoplasms, Castration-Resistant</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065088" MajorTopicYN="N">Steroid Synthesis Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abiraterone acetate</Keyword><Keyword MajorTopicYN="N">Bone-targeted therapy</Keyword><Keyword MajorTopicYN="N">Chemotherapy-naïve</Keyword><Keyword MajorTopicYN="N">Metastatic castration-resistant prostate cancer</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>01</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>04</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25985882</ArticleId><ArticleId IdType="pmc">PMC5056561</ArticleId><ArticleId IdType="pii">S0302-2838(15)00374-7</ArticleId><ArticleId IdType="doi">10.1016/j.eururo.2015.04.032</ArticleId><ArticleId IdType="mid">NIHMS810853</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002913 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002913 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25985882
|texte= Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25985882" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |